The clinical spectrum and causal relationship assessment of checkpoint inhibitor‐associated autoimmune diabetes mellitus (CIADM): A retrospective observational study
Authors:
- 31 March 2026
- journal article
- Published by Wiley in Diabetic Medicine
- Vol. 43 (6) , e70316
Abstract
Aims: This study aims to characterize the clinical spectrum, elucidate the temporal relationship and assess the causality of checkpoint inhibitor‐associated autoimmune diabetes mellitus (CIADM) in a cohort of patients receiving anti‐programmed cell death‐1 (PD‐1)/anti‐programmed death ligand‐1 (PD‐L1) inhibitor therapy. Methods: Individuals who developed CIADM were identified among 4382 hospitalized patients receiving PD‐1/PD‐L1 inhibitor therapy between 2020 and 2024. Demographic characteristics, oncological history, immune checkpoint inhibitor regimens, laboratory parameters (including glycemic control, C‐peptide and islet autoantibodies) and clinical outcomes were systematically collected. Causality was evaluated using the Naranjo algorithm. Results: Among 4382 patients who received PD‐1/PD‐L1 inhibitors, seven (0.16%) were diagnosed with CIADM during the study period. Seven patients were predominantly male, with a median age of 52 years (range: 44–62), and hepatocellular carcinoma was the most common primary malignancy (3/7). All patients developed CIADM after a median of 8 cycles (range: 5–23) of PD‐1/PD‐L1 inhibitors (sintilimab, camrelizumab, envafolimab or atezolizumab). Notably, 86% (6/7) of patients presented with diabetic ketoacidosis (DKA) at onset. Severe pancreatic β‐cell dysfunction was universal, with undetectable fasting and postprandial C‐peptide levels. Islet autoantibodies were positive in only one patient. The Naranjo score indicated a ‘probable’ to ‘highly probable’ causal relationship in all cases. All patients required lifelong insulin therapy. Following glycemic stabilization, immunotherapy was successfully reinitiated in six patients without exacerbating hyperglycemia. Conclusion: CIADM is a severe immune‐related adverse event (irAE) characterized by abrupt onset, a high rate of DKA, and profound insulin deficiency, often in the absence of conventional islet autoantibodies. A definitive causal link exists between PD‐1/PD‐L1 inhibitors and CIADM. Our findings underscore the necessity for proactive glycemic monitoring in patients undergoing ICI therapy, especially in populations such as middle‐aged males with cancers known to have specific demographic profiles (e.g., hepatocellular carcinoma). Importantly, the resumption of immunotherapy is feasible with careful management, highlighting the critical role of a multidisciplinary approach to optimize oncological and metabolic outcomes.Keywords
Funding Information
- Key Research and Development Projects of Shaanxi Province
- Natural Science Basic Research Program of Shaanxi Province
This publication has 23 references indexed in Scilit:
- Immune Checkpoint Inhibitor–Induced Diabetes Across National Cancer Institute Trials That Included PD-1 or PD-L1 AgentsJAMA Oncology, 2026
- Checkpoint Inhibitor-Associated Diabetes Mellitus Following Rapid Pancreatic Metastasis Resolution: Implications for Endocrine Toxicities in ImmunotherapyAACE Endocrinology and Diabetes, 2025
- Hyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendationsJournal for ImmunoTherapy of Cancer, 2025
- Type 1 diabetes risk factors, risk prediction and presymptomatic detection: Evidence and guidance for screeningDiabetes, Obesity and Metabolism, 2025
- Recent advances in immune checkpoint inhibitor-induced type 1 diabetes mellitusInternational Immunopharmacology, 2023
- Hyperglycaemia following immune checkpoint inhibitor therapy—Incidence, aetiology and assessmentDiabetic Medicine, 2023
- Type 1 diabetes related to immune checkpoint inhibitorsBest Practice & Research Clinical Endocrinology & Metabolism, 2022
- Immune checkpoint inhibitor‐induced Type 1 diabetes: a systematic review and meta‐analysisDiabetic Medicine, 2019
- MicroRNA Expression, Survival, and Response to Interferon in Liver CancerNew England Journal of Medicine, 2009
- A Novel Subtype of Type 1 Diabetes Mellitus Characterized by a Rapid Onset and an Absence of Diabetes-Related AntibodiesNew England Journal of Medicine, 2000